Loading...

Sedana Medical

DB:7D2
Snowflake Description

High growth potential with excellent balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
7D2
DB
SEK2B
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

Sedana Medical AB (publ), a medical technology company, develops, markets, and sells medical devices in Sweden. The last earnings update was 18 days ago. More info.


Add to Portfolio Compare Print
7D2 Share Price and Events
7 Day Returns
10.7%
DB:7D2
-2.4%
DE Medical Equipment
-2.3%
DE Market
1 Year Returns
-
DB:7D2
12.3%
DE Medical Equipment
-11.5%
DE Market
7D2 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Sedana Medical (7D2) 10.7% 7% 10.2% - - -
DE Medical Equipment -2.4% -0.9% 5% 12.3% 99.1% 225.6%
DE Market -2.3% -4.9% 0.8% -11.5% 5.7% 6.6%
1 Year Return vs Industry and Market
  • No trading data on 7D2.
  • No trading data on 7D2.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Sedana Medical undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Sedana Medical. This is due to cash flow or dividend data being unavailable. The share price is €9.49.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Sedana Medical's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Sedana Medical's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:7D2 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in SEK SEK-0.52
OM:SEDANA Share Price ** OM (2019-05-24) in SEK SEK107.8
Germany Medical Equipment Industry PE Ratio Median Figure of 9 Publicly-Listed Medical Equipment Companies 35.2x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 20.2x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Sedana Medical.

DB:7D2 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:SEDANA Share Price ÷ EPS (both in SEK)

= 107.8 ÷ -0.52

-205.86x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sedana Medical is loss making, we can't compare its value to the DE Medical Equipment industry average.
  • Sedana Medical is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Sedana Medical's expected growth come at a high price?
Raw Data
DB:7D2 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -205.86x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
103.7%per year
Germany Medical Equipment Industry PEG Ratio Median Figure of 6 Publicly-Listed Medical Equipment Companies 2.97x
Germany Market PEG Ratio Median Figure of 271 Publicly-Listed Companies 1.5x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Sedana Medical, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Sedana Medical's assets?
Raw Data
DB:7D2 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in SEK SEK11.16
OM:SEDANA Share Price * OM (2019-05-24) in SEK SEK107.8
Germany Medical Equipment Industry PB Ratio Median Figure of 13 Publicly-Listed Medical Equipment Companies 4.12x
Germany Market PB Ratio Median Figure of 577 Publicly-Listed Companies 1.77x
DB:7D2 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:SEDANA Share Price ÷ Book Value per Share (both in SEK)

= 107.8 ÷ 11.16

9.66x

* Primary Listing of Sedana Medical.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sedana Medical is overvalued based on assets compared to the DE Medical Equipment industry average.
X
Value checks
We assess Sedana Medical's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Sedana Medical has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Sedana Medical expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
103.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Sedana Medical expected to grow at an attractive rate?
  • Sedana Medical's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Sedana Medical's earnings growth is expected to exceed the Germany market average.
  • Sedana Medical's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:7D2 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:7D2 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 103.7%
DB:7D2 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 49.1%
Germany Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 12.6%
Germany Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 6.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 13.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:7D2 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:7D2 Future Estimates Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 218 50 1
2020-12-31 102 -5 1
2019-12-31 71 -18 1
DB:7D2 Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2019-03-31 60 -3 -10
2018-12-31 58 -6 -7
2018-09-30 53 9 -3
2018-06-30 51 -9 -4
2018-03-31 47 -3 -3
2017-12-31 42 0 -4
2017-09-30 41 -7 -3
2017-06-30 39 10 0
2017-03-31 36 0 0
2016-12-31 34 0 1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Sedana Medical's earnings are expected to grow significantly at over 20% yearly.
  • Sedana Medical's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:7D2 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Sedana Medical Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:7D2 Future Estimates Data
Date (Data in SEK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 2.60 2.60 2.60 1.00
2020-12-31 -0.27 -0.27 -0.27 1.00
2019-12-31 -0.93 -0.93 -0.93 1.00
DB:7D2 Past Financials Data
Date (Data in SEK Millions) EPS *
2019-03-31 -0.52
2018-12-31 -0.38
2018-09-30 -0.22
2018-06-30 -0.28
2018-03-31 -0.27
2017-12-31 -0.45
2017-09-30 -0.17
2017-06-30 0.01
2017-03-31
2016-12-31

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Sedana Medical will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Sedana Medical's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Sedana Medical has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Sedana Medical performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Sedana Medical's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Sedana Medical does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Sedana Medical's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Sedana Medical's 1-year growth to the DE Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Sedana Medical's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Sedana Medical Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:7D2 Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 60.22 -9.75 50.96
2018-12-31 57.90 -6.87 47.41
2018-09-30 53.45 -3.50 42.74
2018-06-30 50.96 -3.76 40.73
2018-03-31 46.74 -3.42 36.71
2017-12-31 41.72 -3.88 31.61
2017-09-30 41.37 -2.97 29.88
2017-06-30 38.79 0.09 27.53
2017-03-31 35.66 -0.32 23.96
2016-12-31 33.73 1.29 22.28
2015-12-31 28.11 -1.21 18.03

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Sedana Medical has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Sedana Medical has efficiently used its assets last year compared to the DE Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Sedana Medical improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Sedana Medical's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Sedana Medical has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Sedana Medical's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Sedana Medical's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Sedana Medical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Sedana Medical's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Sedana Medical's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Sedana Medical has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Sedana Medical Company Filings, last reported 1 month ago.

DB:7D2 Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 215.03 0.00 149.85
2018-12-31 217.81 0.00 159.35
2018-09-30 221.34 0.00 175.15
2018-06-30 223.57 0.00 181.59
2018-03-31 116.60 0.06 79.21
2017-12-31 116.40 0.00 85.32
2017-09-30 116.38 2.77 90.16
2017-06-30 104.87 7.91 100.74
2017-03-31 0.75 22.06 12.62
2016-12-31 1.26 15.06 8.30
2015-12-31 0.45 5.71 3.17
  • Sedana Medical has no debt.
  • Sedana Medical currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Sedana Medical has sufficient cash runway for more than 3 years based on current free cash flow.
  • Sedana Medical has sufficient cash runway for 2.6 years if free cash flow continues to grow at historical rates of 63.2% each year.
X
Financial health checks
We assess Sedana Medical's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Sedana Medical has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Sedana Medical's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Sedana Medical dividends. Estimated to be 0% next year.
If you bought €2,000 of Sedana Medical shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Sedana Medical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Sedana Medical's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:7D2 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Germany Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 1.4%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3.2%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:7D2 Future Dividends Estimate Data
Date (Data in SEK) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Sedana Medical has not reported any payouts.
  • Unable to verify if Sedana Medical's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Sedana Medical's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Sedana Medical has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Sedana Medical's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Sedana Medical's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Sedana Medical afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Sedana Medical has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Sedana Medical's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Christer Ahlberg
COMPENSATION SEK1,420,200
AGE 47
TENURE AS CEO 2.3 years
CEO Bio

Mr. Christer Ahlberg serves as the President and Chief Executive Officer of Sedana Medical AB (publ). He serves as CEO of Sedana Medical AB (publ) since February 01, 2017. Mr. Ahlberg has more than 10 years of experience in leading positions in sales and marketing at e.g. AstraZeneca, Meda and Wyeth. He served as Chief Executive Officer at Eisai AB since 2005 until 2010. He has more than 10 years of experience in leading positions in sales and marketing at e.g. AstraZeneca, Meda and Wyeth. He served as the Chief Executive Officer at Unimedic Group since 2010 until 2016. He served as the Chief Executive Officer at Eisai AB from 2005 to 2010. He served as the Chief Executive Officer at Unimedic AB from 2010 to May 21, 2016 and served as its Senior Director of Corporate Development from May 17, 2016 to March 10, 2017. He serves as a Director of PharmaControl MQL AB.

CEO Compensation
  • Insufficient data for Christer to compare compensation growth.
  • Christer's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Sedana Medical management team in years:

1.3
Average Tenure
47
Average Age
  • The average tenure for the Sedana Medical management team is less than 2 years, this suggests a new team.
Management Team

Christer Ahlberg

TITLE
President & CEO
COMPENSATION
SEK1M
AGE
47
TENURE
2.3 yrs

Ron Farrell

TITLE
VP and Head of R&D and Quality
AGE
62

Maria Engström

TITLE
Chief Financial Officer
AGE
46
TENURE
2.3 yrs

Donat O’Brien

TITLE
Chief Operating Officer
TENURE
0.3 yrs

Robert Dorp

TITLE
VP & Head of Sales
AGE
48

Gunilla Mickelsson

TITLE
Head of Marketing Director
AGE
47
TENURE
0.6 yrs

Peter Sackey

TITLE
Chief Medical Officer
AGE
47
TENURE
1.3 yrs
Board of Directors Tenure

Average tenure and age of the Sedana Medical board of directors in years:

11.3
Average Tenure
63
Average Age
  • The average tenure for the Sedana Medical board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Thomas Eklund

TITLE
Chairman of the Board
COMPENSATION
SEK323K
AGE
51
TENURE
5.3 yrs

Sten Gibeck

TITLE
Director
COMPENSATION
SEK29K
AGE
75
TENURE
14.3 yrs

Bengt Julander

TITLE
Director
COMPENSATION
SEK29K
AGE
65
TENURE
8.3 yrs

Ola Magnusson

TITLE
Director
COMPENSATION
SEK694K
AGE
70
TENURE
14.3 yrs

Mike Ryan

TITLE
Director
COMPENSATION
SEK29K
AGE
61
TENURE
14.3 yrs

Eva Walder

TITLE
Director
AGE
55
TENURE
1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
26. Nov 18 Sell Michael Ryan Individual 23. Nov 18 23. Nov 18 -1,068,083 €7.28 €-7,774,779
26. Sep 18 Sell Ola Magnusson Individual 20. Sep 18 20. Sep 18 -200,000 €8.81 €-1,761,639
25. Sep 18 Sell Ron Farrell Individual 20. Sep 18 20. Sep 18 -167,835 €8.81 €-1,478,323
24. Sep 18 Sell Ron Farrell Individual 19. Sep 18 19. Sep 18 -167,835 €8.78 €-1,473,519
24. Sep 18 Sell Sten Gibeck Individual 20. Sep 18 20. Sep 18 -300,000 €8.81 €-2,642,458
20. Sep 18 Sell Christer Ahlberg Individual 20. Sep 18 20. Sep 18 -30,000 €8.81 €-264,246
12. Jun 18 Sell Ola Magnusson Individual 11. Jun 18 11. Jun 18 -20,000 €6.37 €-127,312
X
Management checks
We assess Sedana Medical's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Sedana Medical has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Sedana Medical AB (publ), a medical technology company, develops, markets, and sells medical devices in Sweden. The company provides AnaConDa and AnaConDa-S, a disposable medical device that enables the administration of volatile anaesthetics; AnaConDa Syringe, a 50/60ml syringe; FlurAbsorb, a charcoal filter for removing halogenated hydrocarbon anaesthetic gases, such as isoflurane or sevoflurane; FlurAbsorb accessory kit comprising lines and connectors for connecting the filter to the ventilator and gas monitor; and FlurAbsorb mounts to hold the filter during scavenging of anaesthetic gas. It also offers isoflurane/sevoflurane and Sevorane QuikFil filling adaptors; gas sampling lines to prevent anaesthetic volatile agents from leaching through the wall of the tube; and Nafion lines to reduce the accumulation of condensate in the anaesthetic gas measuring line and the water trap of the gas monitor. The company was founded in 2005 and is headquartered in Danderyd, Sweden.

Details
Name: Sedana Medical AB (publ)
7D2
Exchange: DB
Founded: 2005
SEK194,141,261
19,276,591
Website: http://www.sedanamedical.com
Address: Sedana Medical AB (publ)
Berga Backe 2,
Danderyd,
Stockholm County, 182 53,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM SEDANA Share Capital OMX Nordic Exchange Stockholm SE SEK 21. Jun 2017
DB 7D2 Share Capital Deutsche Boerse AG DE EUR 21. Jun 2017
Number of employees
Current staff
Staff numbers
37
Sedana Medical employees.
Industry
Health Care Supplies
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/26 22:37
End of day share price update: 2019/05/24 00:00
Last estimates confirmation: 2019/05/09
Last earnings filing: 2019/05/08
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.